GlassScriptPhysician profile
Deborah Stapel
NPI 1316910706
$43,867.40
in general payments reported to CMS, 2019-2025
75 companies · $13K in 2025
The $13K reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,615 · 2022: $4,027 · 2023: $9,924 · 2024: $12K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $23K · Food and Beverage: $12K · Consulting Fee: $300 · Education: $193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $23,115.00 |
| Food and Beverage | $11,617.97 |
| Consulting Fee | $300.00 |
| Education | $192.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $27,151.83 | 2021-2025 | |
| Biogen, INC. | $1,251.86 | 2021-2025 | Tysabri, Leqembi, Vumerity |
| Ucb, INC. | $957.49 | 2021-2025 | Briviact, Rystiggo |
| Acadia Pharmaceuticals INC | $800.51 | 2021-2025 | Nuplazid |
| Grifols USA, LLC | $685.13 | 2021-2025 | Gamunex-C |
| Emd Serono, INC. | $684.42 | 2021-2025 | Mavenclad |
| Teva Pharmaceuticals USA, INC. | $676.71 | 2021-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Lundbeck LLC | $530.90 | 2021-2025 | Vyepti, Rexulti |
| Pfizer INC. | $530.64 | 2021-2025 | |
| Merz Pharmaceuticals, LLC | $496.66 | 2021-2024 | Xeomin |
| Genzyme Corporation | $486.52 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $447.43 | 2021-2025 | Ultomiris |
| Eisai INC. | $429.73 | 2021-2025 | |
| Impel Pharmaceuticals INC. | $410.34 | 2022-2023 | Trudhesa |
| Amneal Pharmaceuticals LLC | $403.08 | 2021-2025 | Crexont, Rytary, Brekiya |
Show all 75 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $396.72 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Amgen INC. | $392.33 | 2021-2024 | Uplizna |
| Upsher-Smith Laboratories LLC | $377.65 | 2021-2023 | |
| Biohaven Pharmaceuticals, INC. | $351.35 | 2021 | |
| Allergan, INC. | $344.34 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $343.13 | 2021-2025 | |
| Alnylam Pharmaceuticals INC. | $340.53 | 2021-2025 | Onpattro, Amvuttra |
| Neurocrine Biosciences, INC. | $328.57 | 2022-2025 | Ingrezza, Ongentys |
| Scilex Pharmaceuticals INC. | $306.68 | 2022-2024 | Ztlido |
| Genentech USA, INC. | $268.55 | 2021-2024 | Ocrevus, Ocrevus Zunovo |
| Lilly USA, LLC | $259.47 | 2021-2025 | Amyvid, Kisunla, Emgality |
| Sk Life Science, INC. | $235.87 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $231.87 | 2022 | |
| Vanda Pharmaceuticals INC. | $220.78 | 2025 | Ponvory |
| Sunovion Pharmaceuticals INC. | $213.03 | 2021-2022 | |
| Horizon Therapeutics Plc | $186.23 | 2021-2022 | |
| Tanabe Pharma America, INC. | $182.38 | 2021-2025 | Radicava |
| Kyowa Kirin, INC. | $176.50 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $168.71 | 2022-2025 | Purified Cortrophin Gel |
| Takeda Pharmaceuticals U.S.A., INC. | $166.84 | 2024-2025 | Hyqvia |
| Amylyx Pharmaceuticals, INC. | $152.21 | 2023-2024 | Relyvrio |
| Banner Life Sciences, LLC | $147.51 | 2021-2023 | |
| Csl Behring | $145.28 | 2021-2024 | Hizentra |
| Supernus Pharmaceuticals, INC. | $144.53 | 2021-2023 | |
| Ge Healthcare | $144.38 | 2022-2024 | |
| Jazz Pharmaceuticals INC. | $127.36 | 2022-2025 | |
| Octapharma USA, INC. | $127.27 | 2023-2024 | Panzyga, Octagam Immune Globulin (Human) |
| Boston Scientific Corporation | $125.21 | 2021-2023 | Vercise |
| Sumitomo Pharma America, INC. | $114.29 | 2023-2024 | Aptiom |
| Celgene Corporation | $103.92 | 2023-2024 | Zeposia |
| Avion Pharmaceuticals | $95.18 | 2022-2023 | Dhivy |
| Axsome Therapeutics, INC. | $83.39 | 2025 | Symbravo |
| Adamas Pharmaceuticals, INC. | $77.58 | 2021 | |
| Mdd US Operations, LLC | $72.29 | 2021-2024 | Gocovri |
| Ipsen Biopharmaceuticals, INC | $72.09 | 2022-2023 | Dysport |
| Acorda Therapeutics, INC | $71.58 | 2021-2024 | Inbrija |
| Almatica Pharma LLC | $54.34 | 2021 | |
| Avadel Cns Pharmaceuticals, LLC | $47.42 | 2024-2025 | Lumryz |
| Janssen Pharmaceuticals, INC | $44.59 | 2021-2023 | Ponvory |
| Aucta Pharmaceuticals, INC. | $41.54 | 2024 | Motpoly Xr |
| Arbor Pharmaceuticals, INC. | $38.79 | 2022 | |
| Tg Therapeutics, INC. | $38.37 | 2023-2024 | |
| Avanir Pharmaceuticals, INC. | $31.98 | 2022 | |
| Azurity Pharmaceuticals, INC. | $28.30 | 2023-2024 | Horizant, Horizant |
| Averitas Pharma INC. | $27.72 | 2023 | Qutenza |
| Nevro Corp. | $26.60 | 2023 | Senza |
| Amicus Therapeutics, INC. | $24.79 | 2025 | |
| Cala Health, INC. | $23.90 | 2025 | Cala Kiq |
| Janssen Biotech, INC. | $23.45 | 2025 | |
| Cycle Pharmaceuticals INC | $20.98 | 2025 | Ormalvi |
| Otsuka America Pharmaceutical, INC. | $19.49 | 2024 | Nuedexta |
| Aprecia Pharmaceuticals, LLC | $19.25 | 2022 | |
| Medtronic, INC. | $17.14 | 2024 | Intellis Adaptivestim |
| Harmony Biosciences LLC | $16.90 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $16.76 | 2025 | |
| Livanova USA, INC. | $15.88 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Tersera Therapeutics LLC | $15.61 | 2025 | Quzyttir |
| Corium, LLC | $13.73 | 2022 | |
| Currax Pharmaceuticals LLC | $12.55 | 2021 | |
| Impel Pharmaceuticals LLC | $8.47 | 2024 | Trudhesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Stapel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.